“The combined impact of these conditions is significant, with reports estimating the cost of excess weight in New Zealand as ...

Associate Health Minister David Seymour says the Government is delivering on its promise to give Kiwis access to more treatments, with Wegovy now ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

The treatment also reduced liver fat — an exciting finding in China, where fatty liver disease is prevalent ... revenue of 704 million Danish kroner ($110 million) in China to Wegovy’s local launch.